Both EGFR and HER2 have been unanimously recognized as prognostic biomarkers in clinical therapies, and HER2 amplification accounts for approximately 25% of breast cancers associated with aggressive disease and poorer survival (Tebbutt et al., 2013; Figueroa-Magalhães et al., 2014). The gene discussed is ERBB2; the disease is breast carcinoma.